In the current drug development pipeline, small and emerging companies are being credited as the drivers of innovation. And although the majority of new drugs in today’s pipelines come from these types of companies, there are still significant challenges they must overcome due to limited funding and resources.1 These resources include R&D productivity, experienced in-house staff, capacity, and access to advanced technology. To avoid interrupting the flow of these novel drugs into the market, small biopharmaceutical companies must find a competent partner that can help them commercialize their products and/or develop the asset to the phase defined by the company’s business model.
There are a growing number of CDMOs in today’s market available to assist with all phases of the drug lifecycle and to provide support for any capabilities a company is lacking. However, contracting a partner for each need requires a significant amount of time and resources to negotiate terms and conditions as well as to oversee the project from development to proof of concept (POC) and beyond. Most small companies do not have that kind of bandwidth. This calls for an alternative solution to help small companies achieve success. One option is a single-source solution, a nontraditional approach that aligns all services through one CDMO to accelerate drug development. This eliminates the silos that can often exist in today’s outsourcing paradigm, increasing both communication and speed.